Figure 1
The expression of AC026356.1 in HCC and its correlation with prognosis. (A) The correlation between AC026356.1 (RP11-817I4.1) expression and overall survival based on TCGA LIHC data, analysed by the online tool GEPIA. (B) AC026356.1 expression in primary HCC tissues (n = 371) and normal liver tissues (n = 50) based on TCGA LIHC data. (C) AC026356.1 expression in HCC tissues with pathological stage I-II (n = 257) or III-IV (n = 90) based on TCGA LIHC data. (D) AC026356.1 expression in HCC tissues with pathological T 1–2 (n = 275) or 3–4 (n = 93) based on TCGA LIHC data. (E) AC026356.1 expression in HCC tissues with grade 1–2 (n = 232) or 3–4 (n = 134) based on TCGA LIHC data. (F) AC026356.1 expression in HCC tissues with fetoprotein (AFP) value < 20 (n = 147) or > 20 (n = 131) based on TCGA LIHC data. For (B–F), data are shown as median with interquartile range. P values were calculated using Mann–Whitney test. (G) AC026356.1 expression in 65 pairs of HCC tissues and matched noncancerous liver tissues was measured by qPCR. Data are shown as median with interquartile range. P values were calculated using Wilcoxon matched-pairs signed rank test. (H) Kaplan–Meier analysis of the correlation between AC026356.1 expression and overall survival in HCC (n = 65). Median AC026356.1 expression value was used as cut-off. HR and P values were calculated using log-rank test. (I) AC026356.1 expression in immortalized liver cell line THLE-2 and HCC cell lines HuH-7, SNU-398, HCCLM3, and Hep3B was measured by qPCR. Data are shown as mean ± standard deviation (SD) of three independent experiments. **P < 0.01, ***P < 0.001, ****P < 0.0001 by one-way ANOVA followed by Dunnett's multiple comparisons test.
